Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Phase 3 Terminated 136 enrolled Bausch & Lomb Incorporated

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.

Timeline

Start: 2013-02
Primary completion: 2013-07
Completion: 2013-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Besifloxacin	Small molecule	0.6 %	Other

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Summary

Timeline

Drugs

Indications